291 related articles for article (PubMed ID: 8674154)
21. Treatment of postoperative nausea and vomiting with single intravenous doses of dolasetron mesylate: a multicenter trial. Dolasetron Mesylate PONV Treatment Study Group.
Kovac AL; Scuderi PE; Boerner TF; Chelly JE; Goldberg ME; Hantler CB; Hahne WF; Brown RA
Anesth Analg; 1997 Sep; 85(3):546-52. PubMed ID: 9296407
[TBL] [Abstract][Full Text] [Related]
22. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy.
Ettinger DS; Eisenberg PD; Fitts D; Friedman C; Wilson-Lynch K; Yocom K
Cancer; 1996 Jul; 78(1):144-51. PubMed ID: 8646710
[TBL] [Abstract][Full Text] [Related]
23. A double-blind, placebo-controlled trial of i.v. dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients.
Bey P; Wilkinson PM; Resbeut M; Bourdin S; Le Floch O; Hahne W; Claverie N
Support Care Cancer; 1996 Sep; 4(5):378-83. PubMed ID: 8883232
[TBL] [Abstract][Full Text] [Related]
24. Single-dose, placebo-controlled, phase I study of oral dolasetron.
Dixon RM; Cramer M; Shah AK; Whitmore J; Benedict CR; Hahne WF
Pharmacotherapy; 1996; 16(2):245-52. PubMed ID: 8820468
[TBL] [Abstract][Full Text] [Related]
25. A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum-induced nausea and emesis.
Sorbe BG; Berglind AM; Andersson H; Boman K; Högberg T; Hallgren M; Schmidt M
Cancer; 1998 Sep; 83(5):1022-32. PubMed ID: 9731907
[TBL] [Abstract][Full Text] [Related]
26. [Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis].
Ariyoshi Y; Nukariya N; Akasaka Y; Suminaga M; Ota J; Ikeda M; Taguchi T
Gan To Kagaku Ryoho; 1997 Jun; 24(8):995-1011. PubMed ID: 9212810
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy.
Burris H; Hesketh P; Cohn J; Moriconi W; Ryan T; Friedman C; Fitts D
Cancer J Sci Am; 1996; 2(2):85-90. PubMed ID: 9166505
[TBL] [Abstract][Full Text] [Related]
28. Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy.
Bhatia A; Tripathi KD; Sharma M
Indian J Med Res; 2003 Jul; 118():33-41. PubMed ID: 14748464
[TBL] [Abstract][Full Text] [Related]
29. Timing of administration of dolasetron affects dose necessary to prevent postoperative nausea and vomiting.
Korttila KT; Jokinen JD
J Clin Anesth; 2004 Aug; 16(5):364-70. PubMed ID: 15374558
[TBL] [Abstract][Full Text] [Related]
30. Acute antiemetic efficacy and safety of dolasetron mesylate, a 5-HT3 antagonist, in cancer patients treated with cisplatin. European Dolasetron Study Group.
Conroy T; Cappelaere P; Fabbro M; Fauser AA; Splinter TA; Spielmann M; Schneider M; Chevallier B; Goupil A; Chauvergne J
Am J Clin Oncol; 1994 Apr; 17(2):97-102. PubMed ID: 8141114
[TBL] [Abstract][Full Text] [Related]
31. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
[TBL] [Abstract][Full Text] [Related]
32. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
[TBL] [Abstract][Full Text] [Related]
33. 5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?
Aapro M; Blower P
Cancer; 2005 Jul; 104(1):1-18. PubMed ID: 15929119
[TBL] [Abstract][Full Text] [Related]
34. Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results.
Hainsworth JD; Hesketh PJ
Semin Oncol; 1992 Dec; 19(6 Suppl 15):14-9. PubMed ID: 1485176
[TBL] [Abstract][Full Text] [Related]
35. Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis.
Bhatia A; Tripathi KD; Sharma M
Indian J Med Res; 2004 Sep; 120(3):183-93. PubMed ID: 15489556
[TBL] [Abstract][Full Text] [Related]
36. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
37. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group.
Fauser AA; Duclos B; Chemaissani A; Del Favero A; Cognetti F; Diaz-Rubio E; Cortes-Funes H; Conte PF; Dressler H
Eur J Cancer; 1996 Aug; 32A(9):1523-9. PubMed ID: 8911112
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
[TBL] [Abstract][Full Text] [Related]
40. Intravenous dolasetron and ondansetron in prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study.
Korttila K; Clergue F; Leeser J; Feiss P; Olthoff D; Payeur-Michel C; Wessel P; Nave S; Hahne W; Brown R
Acta Anaesthesiol Scand; 1997 Aug; 41(7):914-22. PubMed ID: 9265937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]